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FIG 1. A, Effect of inhaled corticosteroids on PC20 to inhaled AMP with
GW870086X. Data are geometric mean 6 geometric SEM. *P < .05
compared with placebo. B, Effect of GW870086X on FENO. Data are
mean 6 SD. *P < .05 difference from placebo.
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agonistGW870086Xprotectsagainstadenosine-
induced bronchoconstriction in asthma
To the Editor:
Inhaled corticosteroids are first-line therapy for treatment of
persistent asthma. The novel dissociated glucocorticoid
GW870086X is a glucocorticoid receptor agonist with potency
similar to that of fluticasone propionate in various human gene
transrepression assays, which reflect the anti-inflammatory
effects, but reduced activity in assays of gene transactivation,
which is thought to mediate many of the adverse effects (AEs) of
glucocorticoids.1,2 The preclinical profile of these dissociated
glucocorticoids suggests that there is potential for improvement
in the therapeutic index beyond that of the currently available
inhaled corticosteroids.1-3 We investigated the potential anti-
inflammatory activity of the novel dissociated glucocorticoid
GW870086X in airway hyperresponsiveness, measured by the
bronchoconstrictor response to inhaled adenosine monophos-
phate (AMP) in subjects with mild asthma.
Details of methods can be found in this article’s Methods
section in the Online Repository at www.jacionline.org. Briefly,
we conducted a double-blind, placebo-controlled, 3-way
cross-over study of GW870086X administered via a dry
powder inhaler (Diskhaler, GlaxoSmithKline, Brentford, United
Kingdom) to investigate its anti-inflammatory activity in airway
responsiveness to AMP in steroid-naive subjects with mild
asthma. Subjects were randomized to GW870086X (1 mg, 3
mg) or placebo administered on days 1 to 7 of each period. The
AMP challenge was performed 2 hours postdosing on day 1 and
at 2, 14, and 26 hours postdosing on day 7. Fractional exhaled
nitric oxide (FENO) was measured on days 1 and 7. Serum osteo-
calcin and 24-hour urinary cortisol measurements were made
on day 7.
Seventeen subjects completed the study as planned (seeTableE1
in this article’s Online Repository at www.jacionline.org for
subjects’ demographic characteristics). There was an increase in
PC20 AMP compared with placebo for GW870086X 1 mg on day
1 at 2 hours postdose and day 7 at 2 and 14 hours postdose and
for GW870086X 3 mg on day 7 at 2 hours postdose (Fig 1, A).
Estimated doubling dose differences for GW870086X 1 and
3 mg were similar across all time points, with mean doubling
dose differences of 1.18 and 1.12 for 1 and 3 mg, respectively.
A significant inhibitory effect of GW870086X on FENO
concentrations at 2, 14, and 26 hours postdose was seen with the
1-mg dose (Fig 1, B). However, 3-mg data were less complete,
and none were significantly different from placebo. The decrease
in FENO significantly correlated with an increase in PC20 AMP in
an analysis including all the data (r 5 0.9). There were no
differences in FEV1 between placebo and GW870086X on day
1 or day 7. Day 1 changes from baseline were (mean, 95% CI)
0.1 (20.03 to 0.23), 0.16 (0.03-0.28), and 0.09 (0.04-0.22) for pla-
cebo, 1 mg, and 3 mg, respectively. There was no evidence of a
reduction compared with placebo in total urinary free cortisol after
7 days of repeat dosing with GW870086X 3 mg, and this was
supported by analysis of the total 24-hour urinary free cortisol
parameter (Fig 2, A). There was no evidence of a difference from 2015 The Authors. Published by Elsevier, Inc. on behalf of the Academy of Allergy,
Asthma& Immunology. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).placebo in weighted mean serum osteocalcin (0-24 hours; Fig 2,
B). Pharmacokinetic analysis of GW870086X can be found in
Tables E2 and E3 in this article’s Online Repository at
www.jacionline.org. The pharmacokinetic disposition of
GW870086X was characterized by a 2-compartment model with
first-order absorption (Ka) and elimination. This model used AD-
VAN4 and TRANS4 subroutines in NONMEM library.
A summary of subjects reporting AEs is presented in Table E4 in
this article’s Online Repository at www.jacionline.org.
GW870086X belongs to a novel class of dissociated
glucocorticoids with anti-inflammatory activity and a reduced
potential for AEs as it enables the glucocorticoid receptor to
transrepress but has less effect on transactivation.1,2 The
anti-inflammatory actions of glucocorticoids are mainly mediated
through gene transrepression, by inhibiting the action of
proinflammatory transcription factors, such as NF-kB, through
histone deacetylation, thereby switching off proinflammatory
genes, which leads to a reduction in inflammatory proteins.1,2 In
contrast, many of the AEs of corticosteroids occur through gene
transactivation2,4,5; a dimer of acetylated glucocorticoid receptor
binds to glucocorticoid response elements in the promoter region
of steroid-sensitive genes to activate (or occasionally suppress)
genes (such as AE genes). In preclinical transrepression assays,
GW870086X had similar or slightly less potency compared with
fluticasone propionate1 (and data on file, GlaxoSmithKline), but
significantly reduced activity in transactivation assays. In
the transactivation-mediated induction of liver enzymes,
GW870086X induced only 30% tyrosine aminotransferase activ-
ity compared with fluticasone propionate. In the transactivation-
mediated suppression of osteocalcin release,GW870086Xshowed
less than half the suppression of osteocalcin by fluticasone propi-
onate (30% vs 65%) (data on file, GlaxoSmithKline).
FIG 2. Effect of GW870086X on 24-hour urinary free cortisol on day 7 (A) and serum osteocalcin on day 7 (B).
Data are mean 6 95% CI.
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bronchoconstrictor response to inhaledAMPchallenge after both a
single dose and at multiple time points after repeat dosing (up to 7
days). This study achieved the primary end point of a significant
reduction in theAMPchallenge versus placebo at 2 hours on day 7.
Serial challenges demonstrated a duration of effect up to 12 hours.
However, at 26 hours on day 7, tolerance to inhaled AMP had
occurred as shownby an increase in PC20 on placebo.
6Wewere un-
able to demonstrate a dose-response between the 1- and3-mgdoses
perhaps because Cmax concentrations measured systemically were
similar in magnitude for both doses. Cmax measurements were
determined for use as a surrogate for delivery. Similar to previous
studies, the AMPand FENO data suggest that GW870086X appears
to follow toU-shaped response, similar to observations in previous
studies.7 There was no reduction in cortisol or osteocalcin after 7
days of repeat dosing with GW870086X. These data support the
potential for reduced bone and metabolic AEs with
GW870086X. The 1- and 3-mg doses were selected empirically
for this study because no cortisol suppression was demonstrated
in a previous study (data on file, GlaxoSmithKline) at these doses
and this findingwasagain confirmed in the present study.The novel
dissociated inhaled glucocorticoid GW870086X was well toler-
ated after repeated dosing with a similar incidence and intensity
of reported AEs between placebo and GW870086X. No serious
AEs were reported.
In conclusion, there was a significant protection against AMP
challenge in subjects with asthma after single and multiple doses
of GW870086X with a potential improved therapeutic index.
The novel dissociated glucocorticoid concept merits further
investigation in clinical studies of inflammatory lung disease
with GW870086X.
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A new case of Fas-associated death domain
protein deficiency and update on treatment
outcomes
To the Editor:
We present a new case of Fas-associated death domain protein
(FADD) deficiency1 (MIM 613759) in a 3-year-old girl of Pakis-
tani descent. Shewas well until age 6 months, when she developed
pneumococcal meningitis from which she recovered fully with
antibiotic therapy. The family history was notable for the death
of 2male siblings from pneumococcal meningitis in infancy, while
another female sibling had died at age 4 months from congenital
cardiac abnormalities (Fig 1). Over the following 12 months, she
had 2 further hospitalizations with fever, irritability, and drowsi-
ness, on one occasion requiring intensive care owing to worsening
METHODS
Study design
This was a 2-center study with a randomized, double-blind, placebo-
controlled, 3-way multiple dose, cross-over design. Treatments were
randomly assigned (3 treatments, 6 sequences). After screening, eligible
subjects entered the study, which comprised three 7-day treatment periods
each separated by a 10- to 28-day washout period, which is consistent with the
pharmacokinetic properties of GW870086X, showing an elimination half-life
of about 15 to 18 hours.E1 No spacer was used for drug administration during
the study.
Subjects had a screening visit 8 to 31 days before treatment and attended a
run-in visit 4 to 10 days after the screening AMP challenge and within 21 days
before treatment. There was a minimum of 4 days between the run-in visit and
the first treatment day. Subjects had 3 treatment periods of 7 days repeat
dosing during which they were randomized to receive 1 mg of GW870086X,
3 mg of GW870086X, or matched placebo inhaled once daily in the
morning using the Diskhaler dry powder inhaler. Subjects were required to
attend the unit on day21 and from predose to 12 hours postdose on day 1. On
day 2, subjects returned on an outpatient basis for dosing and assessments. On
day 7, the subjects were required to stay in the unit until at least 28 hours
postdose. There was a follow-up visit at least 10 to 14 days after the
final treatment period. Inclusion criteria were male, corticosteroid-naive
subjects with asthma aged between 18 and 55 years having a prebronchodi-
lator FEV1 of more than 60% of predicted normal at screening, documented
sensitivity to inhaled AMP, and a baseline FENO level of more than 25 ppb.
All subjects gave their written informed consent before any study-related
procedure. This study was approved by the Brent Medical Ethics Committee
(05/Q0408/89).
Measurement of FENO
Standardized FENO measurements were taken using the NIOX
analyzer (Aerocrine, Solna, Sweden). The FENO level was measured at an
expiratory flow of 50 mL/s, according to standard procedures.E2 The
average of 2 acceptable values was considered for the statistical analysis.
FENO measurements were taken at screening and during each treatment period
on day 1 predose and 2, 14, 26, 48, and 72 hours postadministration on day 7.
In case of concomitant assessments, these measurements were taken
immediately before the AMP challenge test (FENO measurements were not
available in every subject owing to machine failure, so a reduced data
set was available for analysis, especially affecting evaluation of the 3-mg
dose data).
AMP challenge
At screening, subjects underwent an AMP challenge test that was required
to show a provocative concentration of AMP that resulted in a PC20 of less than
80 mg/mL, according to a standardized challenge protocol previously
described.E3,E4 The reproducibility of the challenge was confirmed by a
second challenge performed 4 to 10 days after screening and within 21 days
before treatment. To ensure stability, the run-in PC20 was required to bewithin
1.25 doubling doses of the screening PC20. The criteria for stable bronchocon-
striction in response to inhaled AMP at the run-in visit had to be met. The
highest of 3 FEV1 recordings taken before the administration of the diluent
was used as the presaline baseline. The challenge was not carried out if
FEV1 was less than 60% predicted or the subject had significant asthma
symptoms of wheeze, chest tightness, or cough. Subjects inhaled 0.9% saline,
nebulised from a breath-activated dosimeter of known output (Markos Mefar,
Brescia, Italy). The higher of 2 measurements taken after the inhalation of
saline was used as the postdiluent FEV1 to calculate the PC20 value. Subjects
then inhaled doubling increments of AMP until a 20% or more fall in FEV1
from the postsaline value was achieved or the maximum concentration had
been given. If the highest FEV1 between the 2 duplicates was less than 20%
below the postsaline FEV1 reference, subjects progressed to the next highest
concentration of AMP. Doubling concentrations of AMP ranging from 0.04
to 320 mg/mL were used.
Lung function
FEV1 and forced vital capacity were measured by spirometry (Vitalograph,
Ennis, Ireland). At screening, FEV1 wasmeasured before and 30minutes after
the administration of salbutamol to determine reversibility. During each
treatment period, FEV1 was measured predose and 12 and 24 hours postadmi-
nistration according to American Thoracic Society/European Respiratory
Society standards.E5 For whites of non-European descent, Asians, and blacks,
predicted values for FEV1 and forced vital capacity were to be adjusted for
race as per the European Coal and Steel Community guidelines.E6 Values
were corrected for body temperature and pressure saturated conditions
(saturated with water vapor at body temperature, 378C, and ambient
barometric pressure). Rescue medication (salbutamol) was withheld for at
least 8 hours before the administration of each dose of study medication.
Pharmacokinetics
Predose samples were taken from all subjects. A sparse sampling strategy
was used for the pharmacokinetic sample collection. Four samples were
collected from each subject postdose on days 1 and 7 in each treatment period
as follows: odd numbered subjects—0.08 to 0.5, 1 to 2, 4 to 8, and 22 to 24
hours postdose; even numbered subjects—0.5 to 1, 2 to 4, 8 to 12, and 22 to 24
hours postdose. Plasma samples were analyzed for GW870086X by
GlaxoSmithKline (Ware, United Kingdom) using a validated analytical
method based on protein precipitation, followed by HPLC/MS/MS analysis.
The lower limit of quantification for GW870086X was 20 pg/mL. Modeling
techniques using nonlinear mixed effects methods were used to estimate
individual and population pharmacokinetic parameters from the sparse
sampling of plasma GW870086X concentrations.
Measurements of systemic effects
Osteocalcin was measured in serum on days 1 and 7 predose and at 1, 4, 8,
12, and 24 hours postdose. Serum samples were analyzed for osteocalcin at
Simbec Research Ltd (Merthyr Tydfil, United Kingdom) using a validated
commercial ELISA (Quidel Corporation, San Diego, Calif) with a limit of
quantification of 4.0 ng/mL. The serum osteocalcin weighted mean (0-24
hours) was derived and a statistical analysis was performed, and ratios
comparing each active dose with placebo from the analysis were calculated.
Urine samples were analyzed for cortisol at Simbec Research Ltd using a
validated LC-MS assay with a limit of quantification of 0.5 ng/mL. The total
24-hour urinary free cortisol and total corrected 24-hour urinary free cortisol
(corrected for creatinine) values were derived, and analyzed using a mixed
effects model. Ratios comparing each active dose to placebo from the analysis
were calculated.
Safety assessments
Evaluation of the safety profile included collection and monitoring of any
AEs throughout the study. Heart rate and blood pressure were measured at
screening and in each treatment period before and after drug administration,
and routine clinical laboratory assessments were done at screening and at the
end of the study.
Data analysis
We planned to randomize 20 subjects to provide at least 17 subjects
completing all 3 periods. This sample size provided more than 90% power to
detect a difference of 1.5 doubling doses between GW870086X and placebo
using a 2-sided 95% CI. The ‘‘all subjects’’ population was defined as all
subjects randomized to treatment who received at least 1 dose of study
treatment. This population (n 5 21) was used for all analyses except PC20
AMP and pharmacokinetics. The modified per protocol population excluded
from the all subjects population those subjects with major protocol deviations
relating to inclusion/exclusion criteria that could potentially affect the PC20
AMP analysis. This population (n 5 17) was used to perform a sensitivity
of PC20 AMP. The ‘‘pharmacokinetic concentration’’ population was defined
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as all subjects for whom a pharmacokinetic sample was obtained and
analyzed, and was used for all summaries of pharmacokinetic concentration
data. The ‘‘pharmacokinetic parameter’’ population was defined as all
subjects in the pharmacokinetic concentration population who provided
pharmacokinetic parameters, and was used for all summaries and analysis
of pharmacokinetic parameters.
AMP PC20 was natural log transformed and analyzed using ANOVA for a
cross-over designwith subject (sequence and subjectwithin sequence), period,
and treatment as factors of the model. For each treatment, the least square
mean, pairwise treatment effect, the 95% CI, and probabilities (P values)
were calculated. Estimates for the doubling dose difference (ie, treatment dif-
ference on the log scale) between each active dose and placebowere obtained.
The following rules were applied for PC20 calculation when subjects did not
reach a 20% fall in FEV1: if the last AMP concentration inhaled was the high-
est AMP concentration (320 mg/mL), then the PC20 was set to 320 mg/mL;
if the last inhaled concentration was less than 320 mg/mL and the corres-
ponding fall from baselinewas less than 15%, then the PC20was set tomissing;
and if the fall was more than 15%, then the PC20 was set to the last AMP
concentration inhaled. FEV1 area under the curve comparisons were carried
out using an analysis of covariance for a cross-over design with subject
(sequence and subject within sequence), period, and treatments as factors of
the model and predose values on each treatment as covariate.
FENO concentrations were summarized by treatment and planned relative
time. FENO concentrations were natural log transformed and analyzed using
a mixed effects model. Ratios comparing each active treatment to placebo
at each time point were calculated.
The total 24-hour urinary free cortisol and total corrected 24-hour urinary
free cortisol (corrected for creatinine) values were derived and analyzed.
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Ratios comparing each active dose with placebo from the analysis were
calculated. The serum osteocalcin weighted mean (0-24 hours) was derived
and summarized. A statistical analysis of the serum osteocalcin weighted
mean (0-24 hours) was performed using a mixed effects model and ratios
comparing each active dose with placebo. Safety data AEs, clinical laboratory
evaluations (electrocardiogram, heart rate and blood pressure, and lung
function tests) were summarized by treatment group. No statistical analysis
was performed on the safety data.
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TABLE E1. Subjects’ demographic characteristics
Characteristic N 5 21
Age (y), mean (range) 28 (19-43)
Sex: male, n (%) 21 (100)
Body mass index (kg/m2), mean (range) 24 (19-32)
Race, n (%)
Black 3 (14)
Asian 4 (19)
White 14 (67)
FEV1 (L/min), mean 6 SD 550 6 119
PC20 AMP (mg/mL), median (1 geometric SEM) 16 (19)
FEV1 (% predicted), mean 6 SD 87 6 14
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TABLE E2. Post hoc estimates of GW870086X pharmacokinetic
parameters in subjects with asthma after repeat inhaled doses
GW870086X n Cmax (pg/mL) Tmax (h) AUC
1 mg 19 198 (175, 225) 0.08 (0.08-0.50) 1361 (1111-1667)
3 mg 18 207 (172, 249) 4.50 (0.17-8.03) 3859 (3164-4718)
Geometric mean (95% CIs) presented for Cmax and AUC (0-24). Median (range)
presented for Tmax. AUC, Area under the curve.
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TABLE E3. Population pharmacokinetic parameters for
GW870086X in subjects with asthma after repeat inhaled doses
Parameter Estimate 95% CI Intersubject variability (%)
Ka (h
21) ‘‘slow’’ 0.202 0.13-0.31 62
Ka (h
21) ‘‘fast’’ 1.293 0.65-2.57 ND
CL/F (L/h) 652 499-851 58
V2/F (L) 183 Fixed 89
V3/F (L) 8955 7290-11002 55
Q/F (L/h) 431 1898-9811 67
CL/F, Clearance; Ka, absorption and elimination; ND, not determined; Q/F,
intercompartmental clearance; V2/F, central volume of distribution; V3/F, peripheral
volume of distribution.
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TABLE E4. Safety summary (all AEs reported)
AE
Placebo
(n 5 20)
1 mg
(n 5 19)
3 mg
(n 5 18)
Any event 6 (30) 13 (68) 6 (33)
Rhinitis 1 (5) 4 (21) 2 (11)
Pharyngolaryngeal pain 2 (10) 2 (11) 0
Dyspepsia 1 (5) 2 (11) 0
Headache 0 2 (11) 0
Back pain 0 1 (5) 1 (6)
Cough 1 (5) 1 (5) 1 (6)
Seasonal allergy 0 1 (5) 1 (6)
Ear infection 0 0 1 (6)
Pyrexia 0 1 (5) 0
Diarrhea 0 1 (5) 0
Heart rate increased 0 2 (5) 0
Dysgeusia 0 1 (5) 0
Hepatitis* 0 1 (5) 0
Other 1 (5) 1 (5) 2 (11)
All values are n (%).
*One subject developed EBV-positive hepatitis.
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